Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer

Clinical Breast Cancer

Volumn 10, Issue 6, 2010, Pages 483-488

  Torrisi, Rosalba ^a   Cardillo, Anna ^a   Cancello, Giuseppe ^a   Dellapasqua, Silvia ^a   Balduzzi, Alessandra ^a   Ghisini, Raffaella ^a   Luini, Alberto ^a   Veronesi, Paolo ^a,b   Viale, Giuseppe ^a,b   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

HER2 positivity; Left ventricular ejection fraction

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; PROGESTERONE RECEPTOR; TRASTUZUMAB; TRIPTORELIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; FOLLICULITIS; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; INFLAMMATORY BREAST CANCER; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIMARY TUMOR; RASH; RECURRENT CANCER; SEPSIS; TREATMENT RESPONSE; VOMITING; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PREOPERATIVE CARE; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952278668     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.064     Document Type: Article

References (36)

1. Hortobagyi GN. Anthracyclines in the treatment of breast cancer: an overview. Drugs 1997; 54 (suppl 4): 1-7. (Pubitemid 27487789)
2. Swain SM, Whaley FS, Ewee MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-79. (Pubitemid 36605157)
3. Sparano JA, Winer EP. Liposomal anthracycline for breast cancer. Semin Oncol 2001; 28 (suppl 12): 32-40.
4. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 1997; 54 (suppl 4): 15-21. (Pubitemid 27487791)
5. Verma S, Dent S, Chow BJ, et al. Metastatic breast cancer: the role of pegylated doxorubicin after conventional anthracyclines. Cancer Treat Rev 2008; 34: 391-406.
6. O'Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx / Doxil) versus conventional doxorubicin for first line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-9.
7. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14-20. (Pubitemid 351767337)
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92. (Pubitemid 32222155)
9. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-84.
10. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-9.
11. Smith IE, A'Hern RP, Coombes GA, et al., TOPIC Trial Group. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004; 15: 751-8. (Pubitemid 38714736)
12. Rocca A, Peruzzotti G, Ghisini R, et al. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs 2006; 17: 1201-9. (Pubitemid 44673401)
13. De Boer RH, Saini A, Johnston RD, et al. Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. Breast 2000; 9: 149-55. (Pubitemid 30330645)
14. Chia S, Clemons M, Martin L-A, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006; 24: 2773-8. (Pubitemid 46630575)
15. Andreopoulou E, Gaiotti D, Kim E, et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2007; 7: 690-6. (Pubitemid 47344731)
16. Stickeler E, Klar M, Watermann D, et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat 2009; 117: 591-8.
17. Rivera E, Valero V, Banu A, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21: 3249-54. (Pubitemid 46606257)
18. Von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled open phase IIb study. J Clin Oncol 2001; 19: 3506-15. (Pubitemid 32730088)
19. Bottini A, Berruti A, Brizzi MP, et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 2005; 12: 383-92. (Pubitemid 40896453)
20. Torrisi R, Colleoni M, Veronesi P, et al. Primary therapy with ECF in combination with a GnRH analogue in premenopausal women with hormone receptor positive T2-T4 breast cancer. Breast 2007; 16: 73-80. (Pubitemid 46172859)
21. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006; 24: 3623-8. (Pubitemid 46630536)
22. Torrisi R, Bagnardi V, Pruneri G, et al. Antitumor and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 2007; 97: 802-8. (Pubitemid 47396292)
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST. Eur J Cancer 2009; 45: 228-47.
24. Kuerer HM, Newman LA, Smith TM, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9. (Pubitemid 29075229)
25. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-8. (Pubitemid 39346559)
26. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-68.
27. Gianni L, Norton L, Wolmark N, et al. Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 2009; 27: 4798-808.
28. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
29. Untch M, Rezai M, Loibl S, et al Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28: 2024-31.
30. Ruehl IM, Wirtz RM, Lenhard M, et al. Significance of cyclin D1 expression and amplification status in paraffin-embedded tissue of HER2/neu positive breast cancer patients treated in a neoadjuvant trastuzumab containing protocol (TECHNO-trial). Presented at: the 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX USA December 14-17, 2006.
31. Overmoyer BA. Inflammatory breast cancer novel preoperative therapies. Clin Breast Cancer 2010; 10: 27-32.
32. Mehta RS, Schubbert T, Kong K. Trastuzumab in inflammatory breast cancer. Ann Oncol 2008; 19: 1815-7 .
33. Baselga J, Semiglazov V, Manikhas GM, et al. Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH phase III trial. Eur J Cancer 2007; 5: 193.
34. Soloman M, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008; 8: 21-32. (Pubitemid 351449716)
35. Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus non-inflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10: 7965-71. (Pubitemid 39587537)
36. Dawood S, Broglio K, Kau SW, et al. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 2008; 13: 6-15. (Pubitemid 351206692)